Heron Therapeutics (NASDAQ:HRTX – Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.03) earnings per share for the quarter, FiscalAI reports. Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.The business had revenue of $37.67 million for the quarter, compared to analysts’ expectations of $42.19 million.
Here are the key takeaways from Heron Therapeutics’ conference call:
- Heron withdrew its 2026 financial guidance of $173 million-$183 million in net product sales and $10 million-$20 million in adjusted EBITDA, citing uncertainty around potential generic CINVANTI entry, reduced spending, and strategic alternatives.
- CINVANTI revenue was $21.8 million, down approximately 10% year over year amid branded competition. Heron is appealing a June court decision and preparing for potential generic competition, although management said launch timing and manufacturing and reimbursement factors remain uncertain.
- The acute-care portfolio continued to grow: ZYNRELEF revenue increased 35% year over year to $11.1 million, while APONVIE rose 74% to $4.2 million and reached 23% share of the surgical NK1 segment.
- Second-quarter revenue increased to $37.7 million from $34.7 million in the first quarter, with adjusted EBITDA of $3.2 million; however, the company posted a $5.5 million net loss and ended the quarter with $42.7 million in cash and short-term investments.
- To preserve liquidity and meet revised debt requirements, Heron paused planned second-half sales-force expansion, tightened spending, and agreed to pay down up to $17.5 million of principal under its amended Hercules credit facility. The company is also evaluating strategic alternatives without a set timetable or assurance of a transaction.
Heron Therapeutics Trading Down 31.7%
NASDAQ:HRTX opened at $0.34 on Tuesday. The stock’s 50 day moving average price is $0.44 and its 200 day moving average price is $0.83. Heron Therapeutics has a 52 week low of $0.32 and a 52 week high of $1.57. The company has a market capitalization of $63.41 million, a P/E ratio of -1.86 and a beta of 1.65. The company has a debt-to-equity ratio of 17.51, a quick ratio of 1.51 and a current ratio of 2.53.
Analysts Set New Price Targets
View Our Latest Stock Report on HRTX
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. Rubric Capital Management LP lifted its stake in shares of Heron Therapeutics by 3.3% in the 4th quarter. Rubric Capital Management LP now owns 30,046,828 shares of the biotechnology company’s stock valued at $39,061,000 after purchasing an additional 946,100 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Heron Therapeutics by 9.2% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 11,185,325 shares of the biotechnology company’s stock valued at $14,541,000 after purchasing an additional 946,100 shares during the period. Velan Capital Investment Management LP raised its holdings in Heron Therapeutics by 25.3% in the 3rd quarter. Velan Capital Investment Management LP now owns 8,753,290 shares of the biotechnology company’s stock worth $11,029,000 after acquiring an additional 1,766,546 shares during the period. Millennium Management LLC increased its stake in shares of Heron Therapeutics by 2,785.2% in the fourth quarter. Millennium Management LLC now owns 7,169,908 shares of the biotechnology company’s stock worth $9,321,000 after purchasing an additional 6,921,405 shares during the period. Finally, Tang Capital Management LLC lifted its position in shares of Heron Therapeutics by 81.2% during the 4th quarter. Tang Capital Management LLC now owns 6,250,000 shares of the biotechnology company’s stock worth $8,125,000 after purchasing an additional 2,800,000 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company’s stock.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.
Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.
Featured Stories
- Five stocks we like better than Heron Therapeutics
- Caterpillar’s Blowout Quarter May Point to More Industrial Winners
- Jeff Bezos’ Amazon Sale Looks Less Alarming Than the Headline Suggests
- 3 Overlooked Stocks Analysts Still Like as AI Trades Get Crowded
- China’s Athleisure Boom Is Not Lifting Every Brand Equally
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
